Bracco Diagnostics Inc., a prominent player in the medical imaging industry, is headquartered in the United States. Founded in 1927, the company has established itself as a leader in the development and production of contrast agents and imaging solutions, serving healthcare professionals across North America and beyond. Bracco's core offerings include a range of innovative contrast media for various imaging modalities, such as MRI and CT scans, which enhance diagnostic accuracy and patient care. Renowned for their commitment to quality and safety, Bracco's products are designed to meet the evolving needs of the medical community. With a strong market position, Bracco Diagnostics has achieved significant milestones, including numerous regulatory approvals and partnerships that underscore its reputation for excellence in the field of diagnostic imaging.
How does Bracco Diagnostics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bracco Diagnostics Inc.'s score of 39 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bracco Diagnostics Inc., headquartered in the US, currently does not report specific carbon emissions data for the latest year, as indicated by the absence of emissions figures. The company is a current subsidiary of Bracco S.p.A., which may influence its climate commitments and reporting practices. As of now, Bracco Diagnostics Inc. has not established any documented reduction targets or climate pledges. This lack of specific initiatives suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of direct emissions data, it is essential to consider the broader context of the industry, where many organisations are increasingly focusing on sustainability and carbon footprint reduction. Bracco Diagnostics Inc. may benefit from aligning with industry standards and practices to enhance its environmental performance in the future. Overall, while specific emissions data and reduction targets are not available, the company's affiliation with Bracco S.p.A. may provide a framework for future climate commitments and initiatives.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 49,469,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 41,475,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bracco Diagnostics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
